ATC classification

ATC classification
Name	ATC classification
Caption	Anatomical Therapeutic Chemical classification system
Introduced	1976
Maintained by	WHO Collaborating Centre for Drug Statistics Methodology
Country	International
Type	Drug classification system

ATC classification is an international system for classifying medicines and other medical products by the organ or system on which they act and their therapeutic, pharmacological and chemical properties. Developed and maintained by the WHO Collaborating Centre for Drug Statistics Methodology, it underpins drug utilization research, pharmacoepidemiology and regulatory reporting across jurisdictions such as the European Union, United States, Japan, Canada and Australia. The system interfaces with major international databases and guidelines from bodies like the World Health Organization, European Medicines Agency, International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, United Nations health initiatives and national formularies.

Overview

The ATC scheme assigns active substances to groups at five different levels, ranging from anatomical main group to chemical substance. It was formally introduced in 1976 and has been periodically updated by the WHO Collaborating Centre; updates reflect new medicines approved by regulatory agencies such as the Food and Drug Administration, European Medicines Agency, Medicines and Healthcare products Regulatory Agency and Pharmaceuticals and Medical Devices Agency. ATC codes are widely used alongside identifiers from the International Nonproprietary Name system, the Anatomical Therapeutic Chemical nomenclature framework, and national coding systems in health technology assessment, safety surveillance and reimbursement policy.

Structure and Coding System

The hierarchical ATC code comprises five levels: a single-letter anatomical main group, two-digit therapeutic subgroup, a letter pharmacological/therapeutic subgroup, another letter chemical/therapeutic subgroup, and a two-digit chemical substance identifier. For example, codes link to classes also referenced in the British National Formulary, Micromedex, DailyMed and the European Pharmacopoeia. The system cross-references chemical identifiers such as CAS Registry Number and connects to classification efforts by institutions like the Uppsala Monitoring Centre and projects coordinated through the Organisation for Economic Co-operation and Development. Maintenance includes adding combination products, separating isomers, and accommodating new modalities approved by regulatory agencies.

Classification Criteria and Assignment Process

Assignment of an ATC code follows criteria that consider primary therapeutic use, pharmacological properties and chemical characteristics. National drug authorities, pharmaceutical manufacturers and academic experts may propose codes, which are reviewed by the WHO Collaborating Centre in consultation with stakeholders including representatives from the World Health Organization, the European Centre for Disease Prevention and Control, and drug regulatory bodies. Decisions reference trial data registered with platforms like ClinicalTrials.gov and approval dossiers submitted to agencies such as the Food and Drug Administration and European Medicines Agency. The process balances therapeutic indication, mechanism of action, and predominant clinical use; contentious classifications have involved inputs from advisory committees, expert panels, and international working groups.

Applications in Clinical Practice and Research

Clinicians and researchers use ATC codes for drug utilization studies, comparative effectiveness research, pharmacoepidemiology, and formulary management. Health services analysts employ ATC-linked datasets from national health insurance schemes like those in Germany, Sweden, Denmark, France and Netherlands to monitor prescribing trends, assess adherence, and detect safety signals in collaboration with pharmacovigilance centers such as the Uppsala Monitoring Centre. ATC coding supports meta-analyses and systematic reviews indexed in databases like PubMed, EMBASE, Cochrane Library and registries used in multicenter trials coordinated by institutions like the National Institutes of Health. It is integral to electronic prescribing systems integrated with clinical decision support from vendors and hospital pharmacies in tertiary centers like Mayo Clinic, Johns Hopkins Hospital and Charité – Universitätsmedizin Berlin.

Limitations and Criticisms

Critics point to limitations including difficulties classifying multi-action drugs, novel biologics, gene therapies and combination products whose mechanisms span multiple anatomical systems. Debates echo regulatory challenges faced by agencies such as the Food and Drug Administration and European Medicines Agency when categorizing first-in-class agents or orphan drugs approved under special pathways. The fixed hierarchical structure can obscure off-label uses documented in literature from institutions like The Lancet, New England Journal of Medicine and BMJ Clinical Evidence and can lag behind rapid therapeutic innovation. Additionally, variations in national implementation and mapping to proprietary drug codes (as used by chains like CVS Health, Walgreens Boots Alliance and national health services) produce interoperability challenges for multinational studies.

Comparisons with Other Drug Classification Systems

The ATC system is often compared with systems such as the National Drug Code (NDC) in the United States, the Generic Product Identifier used in some pharmacy software, the British National Formulary categorization, and the Anatomical Therapeutic Chemical Classification System derivatives used in regional formularies. Other taxonomies include the SNOMED CT medicinal product model, the RxNorm terminology maintained by the National Library of Medicine, and pharmacological groupings in reference works like the American Hospital Formulary Service Drug Information. Each system emphasizes different priorities: ATC focuses on therapeutic and chemical properties for international comparisons, while NDC and RxNorm emphasize product-level identifiers for supply chain, billing and electronic health record interoperability. Trade-offs between granularity, clinical relevance and regulatory alignment shape choice of system in research, medicine procurement and health policy in organizations such as the World Health Organization and national health agencies.

Category:Drug classification systems